Latest Share Chat

REMOVE ADS

PureTech Share News (PRTC)

PureTech Information

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes

Get Live Data

132.00 -0.60 (-0.45%)

Bid:

131.40

Ask:

132.80

Spread: 1.40 (1.065%)

Market Cap: £321.31m

Last checked at -

Intraday PureTech Share Chart

REMOVE ADS

PureTech Gets Positive Data From 'Project: Evo' Trial In ADHD

Wed, 28th Oct 2015 17:11

LONDON (Alliance News) - PureTech Health PLC said Wednesday that its operating company, Akili Interactive Labs Inc, reported positive data from its study of its videogame-like treatment 'Project: EVO' in attention deficit hyperactivity disorder.

The company said that the study showed "statistically significant improvements on multiple outcomes measuring attention, impulsivity and working memory in children with ADHD."

'Project: Evo' is a diagnostic tool, that uses a videogame interface to assess a patient.

"We are pleased with Akili's pilot study in ADHD. One in 10 children in the US have been diagnosed with ADHD and, based on the strength of these data, we look forward to Akili initiating a pivotal study to further validate the efficacy and safety of Project: EVO as a potential new treatment option," said Chief Executive Officer Daphne Zohar in a statement.

Shares in PureTech closed up 1.0% at 150.00 pence Wednesday.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews